Inovio Pharmaceuticals INO Stock
Inovio Pharmaceuticals Price Chart
Inovio Pharmaceuticals INO Financial and Trading Overview
Inovio Pharmaceuticals stock price | 1.58 USD |
Previous Close | 0.5 USD |
Open | 0.49 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 900 |
Day's Range | 0.49 - 0.52 USD |
52 Week Range | 0.47 - 2.82 USD |
Volume | 10.75M USD |
Avg. Volume | 7.46M USD |
Market Cap | 132.97M USD |
Beta (5Y Monthly) | 1.067605 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.95 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.33 USD |
INO Valuation Measures
Enterprise Value | -61588228 USD |
Trailing P/E | N/A |
Forward P/E | -1.3318421 |
PEG Ratio (5 yr expected) | -0.02 |
Price/Sales (ttm) | 13.064544 |
Price/Book (mrq) | 0.66767806 |
Enterprise Value/Revenue | -6.051 |
Enterprise Value/EBITDA | 0.261 |
Trading Information
Inovio Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.067605 |
52-Week Change | -68.12% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.82 USD |
52 Week Low | 0.47 USD |
50-Day Moving Average | 0.71 USD |
200-Day Moving Average | 1.45 USD |
INO Share Statistics
Avg. Volume (3 month) | 7.46M USD |
Avg. Daily Volume (10-Days) | 9.98M USD |
Shares Outstanding | 262.74M |
Float | 258.42M |
Short Ratio | 5.41 |
% Held by Insiders | 1.57% |
% Held by Institutions | 49.32% |
Shares Short | 42.78M |
Short % of Float | 18.64% |
Short % of Shares Outstanding | 16.28% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -2355.95% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -42.093% |
Return on Equity (ttm) | -87.099% |
Income Statement
Revenue (ttm) | 10.18M USD |
Revenue Per Share (ttm) | 0.04 USD |
Quarterly Revenue Growth (yoy) | -42.29% |
Gross Profit (ttm) | -177388235 USD |
EBITDA | -235906192 USD |
Net Income Avi to Common (ttm) | -241393664 USD |
Diluted EPS (ttm) | -0.93 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 223.75M USD |
Total Cash Per Share (mrq) | 0.85 USD |
Total Debt (mrq) | 31.16M USD |
Total Debt/Equity (mrq) | 15.64 USD |
Current Ratio (mrq) | 4.241 |
Book Value Per Share (mrq) | 0.758 |
Cash Flow Statement
Operating Cash Flow (ttm) | -190997792 USD |
Levered Free Cash Flow (ttm) | -118192656 USD |
Profile of Inovio Pharmaceuticals
Country | United States |
State | PA |
City | Plymouth Meeting |
Address | 660 West Germantown Pike |
ZIP | 19462 |
Phone | 267 440 4200 |
Website | https://www.inovio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 184 |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Q&A For Inovio Pharmaceuticals Stock
What is a current INO stock price?
Inovio Pharmaceuticals INO stock price today per share is 1.58 USD.
How to purchase Inovio Pharmaceuticals stock?
You can buy INO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inovio Pharmaceuticals?
The stock symbol or ticker of Inovio Pharmaceuticals is INO.
Which industry does the Inovio Pharmaceuticals company belong to?
The Inovio Pharmaceuticals industry is Biotechnology.
How many shares does Inovio Pharmaceuticals have in circulation?
The max supply of Inovio Pharmaceuticals shares is 36.67M.
What is Inovio Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Inovio Pharmaceuticals PE Ratio is now.
What was Inovio Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Inovio Pharmaceuticals EPS is -3.95 USD over the trailing 12 months.
Which sector does the Inovio Pharmaceuticals company belong to?
The Inovio Pharmaceuticals sector is Healthcare.
Inovio Pharmaceuticals INO included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
9.99B USD — | 14784.03 USD — | 16292.28 USD — | — - | 9.99B USD — |
NASDAQ Biotechnology Total Retu XNBI | 4172.84 USD — |
-1.22
|
— — | 4004.28 USD — | 4291.75 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7634.31 USD — |
+0.11
|
— — | 7233.89 USD — | 7972.89 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}